Nitrogen-containing heterocyclic compound

Patent metadata

Field	Value
Publication number	US-2016152603-A1
Application number	US-201615013625-A
Country	US
Kind code	A1
Filing date	Feb 2, 2016
Priority date	Apr 23, 2014
Publication date	Jun 2, 2016
Grant date	—

Abstract

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof.

wherein each symbol is as described in the specification, or a salt thereof.

First claim

1 - 13 . (canceled)

14 . 2-[(3S,4S)-4-Hydroxytetrahydro-2H-pyran-3-yl]-6-(4-methoxybenzyl)-4,5-dimethyl-2,3-dihydro-1H-isoindol-1-one, or a salt thereof.

15 - 16 . (canceled)

17 . A medicament comprising 2-[(3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl]-6-(4-methoxybenzyl)-4,5-dimethyl-2,3-dihydro-1H-isoindol-1-one or a salt thereof, and a pharmaceutically acceptable carrier.

18 - 23 . (canceled)

Assignees

• Takeda Pharmaceutical

Inventors

• Yamada Masami
• Suzuki Shinkichi
• Sugimoto Takahiro
• Nakamura Minoru
• Sakamoto Hiroki
• Kamata Makoto

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title